Literature DB >> 25894944

Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms.

Chiara Saponaro1, Melania Gaggini, Amalia Gastaldelli.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is an independent risk factor for advanced liver disease, type 2 diabetes (T2DM), and cardiovascular diseases. The prevalence of NAFLD in the general population is around 30 %, but it is up to three times higher in those with T2DM. Among people with obesity and T2DM, the NAFLD epidemic also is worsening. Therefore, it is important to identify early metabolic alterations and to prevent these diseases and their progression. In this review, we analyze the pathophysiologic mechanisms leading to NAFLD, particularly, those common to T2DM, such as liver and muscle insulin resistance. However, it is mainly adipose tissue insulin resistance that results in increased hepatic de novo lipogenesis, inflammation, and lipotoxicity. Although genetics predispose to NAFLD, an unhealthy lifestyle, including high-fat/high-sugar diets and low physical activity, increases the risk. In addition, alterations in gut microbiota and environmental chemical agents, acting as endocrine disruptors, may play a role.

Entities:  

Mesh:

Year:  2015        PMID: 25894944     DOI: 10.1007/s11892-015-0607-4

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  131 in total

1.  Liver fibrosis in overweight patients.

Authors:  V Ratziu; P Giral; F Charlotte; E Bruckert; V Thibault; I Theodorou; L Khalil; G Turpin; P Opolon; T Poynard
Journal:  Gastroenterology       Date:  2000-06       Impact factor: 22.682

Review 2.  Impact of environmental endocrine disrupting chemicals on the development of obesity.

Authors:  Retha R Newbold
Journal:  Hormones (Athens)       Date:  2010 Jul-Sep       Impact factor: 2.885

3.  Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects.

Authors:  Anna Kotronen; Leena Juurinen; Antti Hakkarainen; Jukka Westerbacka; Anja Cornér; Robert Bergholm; Hannele Yki-Järvinen
Journal:  Diabetes Care       Date:  2007-10-12       Impact factor: 19.112

Review 4.  Can NASH be diagnosed, graded, and staged noninvasively?

Authors:  Garfield A Grandison; Paul Angulo
Journal:  Clin Liver Dis       Date:  2012-06-26       Impact factor: 6.126

5.  NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis.

Authors:  Aileen Dela Peña; Isabelle Leclercq; Jacqueline Field; Jacob George; Brett Jones; Geoffrey Farrell
Journal:  Gastroenterology       Date:  2005-11       Impact factor: 22.682

6.  The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis.

Authors:  Anneloes E Bohte; Jochem R van Werven; Shandra Bipat; Jaap Stoker
Journal:  Eur Radiol       Date:  2010-07-31       Impact factor: 5.315

7.  Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers.

Authors:  Indra Neil Guha; Julie Parkes; Paul Roderick; Dipanker Chattopadhyay; Richard Cross; Scott Harris; Philip Kaye; Alastair D Burt; Steve D Ryder; Guruprasad P Aithal; Christopher P Day; William M Rosenberg
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

Review 8.  Metabolic stress in insulin's target cells leads to ROS accumulation - a hypothetical common pathway causing insulin resistance.

Authors:  Jan W Eriksson
Journal:  FEBS Lett       Date:  2007-06-27       Impact factor: 4.124

9.  Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.

Authors:  S A Harrison; D Oliver; H L Arnold; S Gogia; B A Neuschwander-Tetri
Journal:  Gut       Date:  2008-04-04       Impact factor: 23.059

10.  Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD.

Authors:  Steven G Pearce; Nirav C Thosani; Jen-Jung Pan
Journal:  Biomark Res       Date:  2013-02-04
View more
  40 in total

1.  Leaves of Lippia triphylla improve hepatic lipid metabolism via activating AMPK to regulate lipid synthesis and degradation.

Authors:  Yi Zhang; Mengyang Liu; Qian Chen; Tingting Wang; Haiyang Yu; Jingqi Xu; Tao Wang
Journal:  J Nat Med       Date:  2019-05-18       Impact factor: 2.343

Review 2.  Endocrine-disrupting chemicals and fatty liver disease.

Authors:  Charles E Foulds; Lindsey S Treviño; Brian York; Cheryl L Walker
Journal:  Nat Rev Endocrinol       Date:  2017-05-19       Impact factor: 43.330

3.  Comparison of new and conventional versions of model-based iterative reconstruction in reduced-dose computed tomography for diagnosis of hepatic steatosis.

Authors:  Koichiro Yasaka; Masaki Katsura; Jiro Sato; Masaaki Akahane; Izuru Matsuda; Kuni Ohtomo
Journal:  Jpn J Radiol       Date:  2016-02-23       Impact factor: 2.374

4.  Transfer of glucose hydrogens via acetyl-CoA, malonyl-CoA, and NADPH to fatty acids during de novo lipogenesis.

Authors:  Getachew Debas Belew; Joao Silva; Joao Rito; Ludgero Tavares; Ivan Viegas; Jose Teixeira; Paulo J Oliveira; Maria Paula Macedo; John G Jones
Journal:  J Lipid Res       Date:  2019-10-01       Impact factor: 5.922

5.  Non-alcoholic Fatty Liver Disease in Morbidly Obese Individuals Undergoing Bariatric Surgery: Prevalence and Effect of the Pre-Bariatric Very Low Calorie Diet.

Authors:  Katherine J P Schwenger; Sandra E Fischer; Timothy D Jackson; Allan Okrainec; Johane P Allard
Journal:  Obes Surg       Date:  2018-04       Impact factor: 4.129

6.  Organ fat in Latino youth at risk for type 2 diabetes.

Authors:  Janiel L Pimentel; Kiley B Vander Wyst; Erica G Soltero; Armando Peña; Houchun H Hu; Smita S Bailey; Amber Pokorney; Stephanie L Ayers; Ana Martinez Valencia; Micah L Olson; Gabriel Q Shaibi
Journal:  Pediatr Diabetes       Date:  2022-01-19       Impact factor: 4.866

Review 7.  NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic Outlook.

Authors:  Alberto Nascè; Karim Gariani; François R Jornayvaz; Ildiko Szanto
Journal:  Antioxidants (Basel)       Date:  2022-06-09

8.  The Morbidity and Comorbidity of Nonalcoholic Fatty Liver Disease and Different Glucose Intolerance Strata in a Community-Based Chinese Population.

Authors:  Xiuying Zhang; Xianghai Zhou; Xueyao Han; Zuodi Fu; Lianying Wang; Yufeng Li; Linong Ji
Journal:  Metab Syndr Relat Disord       Date:  2020-05-27       Impact factor: 1.894

9.  Plant-derived oleanolic acid ameliorates markers associated with non-alcoholic fatty liver disease in a diet-induced pre-diabetes rat model.

Authors:  Mlindeli Gamede; Lindokuhle Mabuza; Phikelelani Ngubane; Andile Khathi
Journal:  Diabetes Metab Syndr Obes       Date:  2019-10-01       Impact factor: 3.168

10.  Effect of SGLT-2 Inhibitors on Non-alcoholic Fatty Liver Disease among Patients with Type 2 Diabetes Mellitus: Systematic Review with Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials.

Authors:  Kai Wei Lee; Navin Kumar Devaraj; Siew Mooi Ching; Sajesh K Veettil; Fan Kee Hoo; Inas Deuraseh; Man Jun Soo
Journal:  Oman Med J       Date:  2021-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.